// App-Quantinova.ai

45 : Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Researchers

Presenter

  • Gyorgy Bodoky

Principal Investigators

  • Marian Gil-Delgado

  • Stefano Cascinu

  • Oleg N. Lipatov

  • David Cunningham

  • Eric Van Cutsem

  • Kei Muro

  • Kumari Chandrawansa

  • Astra M. Liepa

  • Roberto Carlesi

  • Atsushi Ohtsu

  • Hansjochen Wilke

Medical Centers

  • Szent László Hospital, Budapest, Hungary

  • Hôpital La Salpêtrière, Paris, France

  • Clinica di Oncologia Medica, Universita Politecnica delle Marche, AO Ospedali Riuniti, Ancona, Italy

  • Bashkortostan Clinical Oncology Center, Ufa, Russia

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Eli Lilly and Company, Bridgewater, NJ

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly Italia Sesto Fiorentino Italy

  • Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan

  • Kliniken Essen Mitte Center of Pallative Care, Essen, Germany

Locations

  • Hungary

  • France

  • Italy

  • Russia

  • United Kingdom

  • Belgium

  • Japan

  • United States

  • Germany

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Transthyretin

Drug/Treatment

  • Ramucirumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01170663

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved